374633-27-9 Usage
Uses
Used in Pharmaceutical Industry:
4-BROMO-6-INDOLECARBOXYLIC ACID is used as a building block for the synthesis of various pharmaceuticals and bioactive molecules, leveraging its unique structure and functional groups to create novel compounds with therapeutic potential.
Used in Medicinal Chemistry Research:
4-BROMO-6-INDOLECARBOXYLIC ACID is used as a starting material in the development of new drugs, particularly those targeting inflammation and cancer. Its potential anti-inflammatory and antitumor properties make it a promising candidate for further research and drug discovery.
Used in Coordination Chemistry:
4-BROMO-6-INDOLECARBOXYLIC ACID is used as a ligand in coordination chemistry, enabling the formation of metal complexes with unique properties and potential applications in various fields, such as catalysis and materials science.
Used in Catalyst and Material Preparation:
4-BROMO-6-INDOLECARBOXYLIC ACID is used in the preparation of metal-based catalysts and materials, taking advantage of its ability to form stable complexes with metal ions. These catalysts and materials can be employed in various chemical reactions and industrial processes, enhancing their efficiency and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 374633-27-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,7,4,6,3 and 3 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 374633-27:
(8*3)+(7*7)+(6*4)+(5*6)+(4*3)+(3*3)+(2*2)+(1*7)=159
159 % 10 = 9
So 374633-27-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H6BrNO2/c10-7-3-5(9(12)13)4-8-6(7)1-2-11-8/h1-4,11H,(H,12,13)
374633-27-9Relevant academic research and scientific papers
ACYLHYDRAZONES AS KINASE MODULATORS
-
Page/Page column 39, (2010/11/24)
Abstract The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
